on Eckert & Ziegler Strahlen- Und Medizintechnik AG (isin : DE0005659700)
Eckert & Ziegler Seeks Approval for GalliaPharm® in Japan
Berlin-based Eckert & Ziegler Radiopharma GmbH has submitted its GalliaPharm® 68Ge/68Ga Radionuclide Generator for approval by Japan's Ministry of Health, Labour and Welfare (MHLW). This move could enhance diagnostic tools available in Japan, particularly in oncology, through products like 68Ga-PSMA-11. Novartis Pharma K.K. will oversee safety and distribution in Japan.
The approval of GalliaPharm® in Japan promises new possibilities for precise diagnostic imaging in nuclear medicine, potentially improving early disease detection and patient outcomes. The generator is used widely for producing Gallium-68, which is essential for positron emission tomography (PET) imaging.
Dr. Deljana Werner, from Eckert & Ziegler, emphasized the importance of this step with the MHLW. It reflects the company's global commitment to advancing nuclear medicine and supporting local healthcare through innovative imaging tools.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news